PMID- 33567084
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20221207
IS  - 2702-3648 (Electronic)
IS  - 2702-3648 (Linking)
VI  - 121
IP  - 2
DP  - 2021 Feb 1
TI  - SGLT2 inhibitors: a narrative review of efficacy and safety.
PG  - 229-239
LID - 10.1515/jom-2020-0153 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a cardio-renal-metabolic condition that is 
      frequently associated with multiple comorbidities, including atherosclerotic 
      cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease 
      (CKD). The sodium-glucose co-transporter-2 (SGLT2) inhibitors, which lower 
      glycated hemoglobin, fasting and postprandial plasma glucose levels, body weight, 
      and blood pressure, as well as reduce the risk of a range of cardiovascular and 
      renal outcomes without increasing hypoglycaemic risk, have heralded a paradigm 
      shift in the management of T2DM. These drugs are compatible with most other 
      glucose-lowering agents and can be used in patients with a wide range of comorbid 
      conditions, including ASCVD, HF, and CKD, and in those with estimated glomerular 
      filtration rates as low as 30 mL/min/1.73 m2. However, there are 
      misunderstandings surrounding the clinical implications of SGLT2 inhibitors' 
      mechanism of action and concerns about the key adverse events with which this 
      class of drugs has been associated. This narrative review summarizes the data 
      that support the efficacy of SGLT2 inhibitors in reducing the risks of 
      cardiovascular and renal outcomes in patients with T2DM and comorbid conditions 
      and clarifies information relating to SGLT2 inhibitor-related adverse events.
FAU - Nelinson, Donald S
AU  - Nelinson DS
AD  - American College of Osteopathic Internists , Rockville , MD 20852 , USA.
FAU - Sosa, Jose M
AU  - Sosa JM
AD  - Department of Medicine, Division of Cardiology , Brooke Army Medical Center San 
      Antonio , TX 78234 , USA.
FAU - Chilton, Robert J
AU  - Chilton RJ
AD  - Professor of Medicine, Department of Medicine, Division of Cardiology , The 
      University of Texas Health Science Center at San Antonio , San Antonio , TX 78284 
      , USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - J Osteopath Med
JT  - Journal of osteopathic medicine
JID - 101776472
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Diabetes Mellitus, Type 2
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents
MH  - Renal Insufficiency, Chronic
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
EDAT- 2021/02/11 06:00
MHDA- 2021/09/10 06:00
CRDT- 2021/02/10 17:14
PHST- 2021/02/10 17:14 [entrez]
PHST- 2021/02/11 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
AID - 2765420 [pii]
AID - 10.1515/jom-2020-0153 [doi]
PST - ppublish
SO  - J Osteopath Med. 2021 Feb 1;121(2):229-239. doi: 10.1515/jom-2020-0153.